Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 3, 2000, Pages 343-347

  Regazzi, M B ^a   Villani, P ^a   Maserati, R ^a   Seminari, E ^a   Pan, A ^b   LoCaputo, F ^c   Gambarana, E ^a   Fiocchi, C ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG ACTIVITY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ULTRAVIOLET RADIATION;

EID: 0034007356     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.3.343     Document Type: Article

References (22)

1. Rachlis, A. R. & Zarowny, D. P. (1998). Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. Canadian Medical Association Journal 158, 496-505.
2. Department of Health and Human Services & Henry J. Kaiser Family Foundation. (1998). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Annals of Internal Medicine 128, 1079-100.
3. Carpenter, C. C., Fishl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M. & Katzenstein, D. A. (1998). Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association 280, 78-86.
4. Moyle, G. J., Gazzard, B. G., Cooper, D. A. & Gatell, J. (1998). Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs 55, 383-404.
5. Gulik, R. M., Mellors, J. H., Havlir, D., Eron, J. J., Gonzalez, C. & McMahon, D. (1997). Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337, 734-9.
6. Montaner, J. S., Reiss, P., Cooper, D., Vella, S., Harris, M. & Conway, B. (1998). A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS trial. Journal of the American Medical Association 279, 930-7.
7. Patick, A. K., Mo, H., Markowitz, M., Appelt, K., Wu, B. & Musick, L. (1996). Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy 40, 292-7.
8. Markowitz, M., Conant, M., Hurley, A., Schluger, R., Duran, M. & Peterkin, J. (1998). A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. Journal of Infectious Diseases 177, 1533-40.
9. Wu, E. Y., Wilkinson, J. M., II, Naret, D. G., Daniels, V. L., Williams, L. J. & Khalil, D. A. (1997). High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. Journal of Chromatography B. Biochemical Sciences and Applications 695, 373-80.
10. Simed. (1996). P-PHARM User's Guide, 2nd edn. Simed, Creteil, France.
11. Gomeni, R., Pineau, G. & Mentrè, F. (1994). Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Research 14, 2321-6.
12. Gathe, J., Jr, Burkhardt, B., Hawley, P., Conant, M., Peterkin, J. & Chapman, S. (1996). A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs. stavudine (d4T) alone. In Program and Abstracts of the Eleventh International Conference on AIDS, Vancouver, 1996. Abstract MoB.413, p. 25.
13. Moyle, G., Youle, M., Chapman, S. et al. (1995). A phase II dose escalation study of the Agouron protease inhibitor AG 1343. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. American Society for Microbiology, Washington, DC.
14. Becker, M. I., Wilson, D., Yuen, N. et al. (1997). An expanded access program with Viracept (nelfinavir mesylate). In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract 262. American Society for Microbiology, Washington, DC.
15. Quart, B. D., Chapman, S. K., Peterkin, J., Webber, S. & Oliver, S. (1995). Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 - a novel HIV protease inhibitor. In Proceedings of the Second National Conference on Human Retroviruses and Related Infections, Washington, 1995. Abstract LB3, p. 167.
16. Kerr, B. M., Yuen, G. J., Sandoval, T. et al. (1997). The pharmacokinetics (PK) of nelfinavir administered alone and with ketoconazole (K) in healthy volunteers. In Program and Abstracts of the Ninety-Eighth American Society Congress for Clinical Pharmacology and Therapeutics, San Diego, 1997. Abstract 147.
17. Markowitz, M., Conant, M., Hurley, A. et al. (1995). Phase I/II dose range-finding study of the HIV protease inhibitor AG1343. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. American Society for Microbiology, Washington, DC.
18. Pedneault, L., Elion, R., Adler, M. et al. (1996). A pilot study of safety and antiviral activity of the combination of stavudine, didanosine and nelfinavir in HIV-infected subjects. Abstract. AIDS 10, Suppl. 2, 17.
19. Fiske, W. D., Benedek, I. H., White, S. J. et al. (1997). Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract I 174. American Society for Microbiology, Washington, DC.
20. Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Tija, J. F. & Halifax, K. L. (1998). The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 12, 1163-7.
21. Skowron, G., Leoung, G., Kerr, B., Dusek, A., Anderson, R. & Beebe, S. (1998). Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 12, 1243-4.
22. Fiske, W. D., Benedek, I. H., White, S. J., Pepperess, K. A., Joseph, J. L. & Kornhauser, D. M. (1998). Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. In Program and Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, 1998. Abstract 349, p. 144.